CNS Drug Manufacturer in India

WHO-GMP certified Central Nervous System medicine manufacturing across tablets, capsules, oral syrups, suspensions and oral solutions — antidepressants, anxiolytics, antipsychotics, antiepileptics and sedatives for domestic supply, institutional procurement and international export.

Key Highlights

WHO-GMP
Certified Facility
Antidepressants
· Antiepileptics · CNS Range
15+ Countries
Supplied
DCGI Approved
Formulations

Request A Product List

Download Capability Brochure

About CNS / Neurology

CNS medicine manufacturing
expertise at 9M India

9M India manufactures a comprehensive range of Central Nervous System (CNS) medicines from a WHO-GMP certified facility in Birkoni, Chhattisgarh. Our CNS portfolio covers antidepressants, anxiolytics, antipsychotics, antiepileptics and sedatives — across tablets, capsules, oral syrups, oral suspensions and oral solutions for the full spectrum of CNS therapeutic indications.

CNS medicines present particular formulation challenges — narrow therapeutic indices for antiepileptics, Schedule H regulatory requirements across most CNS drug classes, complex absorption kinetics for modified-release neurological formulations and the specific paediatric dosing requirements for antiepileptic suspensions and solutions. 9M India's formulation and manufacturing capability addresses each of these requirements with validated processes and complete regulatory documentation.

Antiepileptic formulations — Levetiracetam, Carbamazepine, Phenytoin, Valproate — are among the most consistently tendered CNS medicines in government health programmes and export markets, particularly in Africa where epilepsy prevalence rates are high. Our CNS liquid formulations including Levetiracetam oral solution, Carbamazepine suspension and Diazepam oral solution are specifically developed for paediatric and institutional requirements.

CNS medicines across antidepressants, antiepileptics, anxiolytics, antipsychotics, sedatives
Oral solid (tablets, capsules) and oral liquid (syrups, suspensions, solutions) formats
Antiepileptic oral solutions for paediatric institutional supply
Schedule H compliant manufacturing and documentation
WHO-GMP certified — DCGI-approved — export-ready

Enquire Now

Our Capabilities

CNS drug manufacturing capabilities at 9M India

01

Sertraline tablets (50mg, 100mg) — SSRI antidepressant in film-coated tablet format. Fluoxetine capsules and tablets — SSRI for depression, OCD and anxiety disorders. Escitalopram tablets — SSRI antidepressant. Clonazepam tablets (0.25mg, 0.5mg, 1mg, 2mg) — benzodiazepine anxiolytic and antiepileptic. Low-dose tablet manufacturing for antidepressants and anxiolytics applies enhanced blend uniformity and content uniformity protocols — critical for CNS drugs with narrow dose ranges.
02

Levetiracetam tablets (250mg, 500mg, 1000mg) — newer generation antiepileptic with strong domestic and export demand. Carbamazepine tablets (100mg, 200mg, 400mg) in standard and extended-release formats — including chewable tablet format for paediatric use. Phenytoin sodium tablets (100mg) — long-established antiepileptic. Valproate tablets — immediate-release and enteric-coated. Lamotrigine tablets (25mg, 50mg, 100mg) — used in epilepsy and bipolar disorder. Antiepileptic drugs require strict content uniformity validation given narrow therapeutic index — all 9M India antiepileptic tablet batches tested by validated HPLC assay methods.
03

Haloperidol tablets (0.5mg, 1.5mg, 5mg, 10mg) — typical antipsychotic for schizophrenia and psychotic disorders. Risperidone tablets (0.5mg, 1mg, 2mg, 3mg, 4mg) — atypical antipsychotic. Olanzapine tablets including orally disintegrating tablet (ODT) format — atypical antipsychotic for schizophrenia and bipolar disorder. ODT manufacturing requires validated disintegration performance and palatability as primary quality attributes alongside assay and content uniformity.
04

Levetiracetam oral solution (100mg/mL) — for paediatric epilepsy management where tablet swallowing is not feasible. Carbamazepine suspension (100mg/5mL) — antiepileptic suspension for paediatric use. Diazepam oral solution — sedative and antiepileptic. Promethazine syrup — CNS antihistamine and sedative. All CNS oral liquid formulations manufactured with Schedule H-compliant labelling, child-resistant closures and dose-accurate administration devices. Dose uniformity validated throughout shelf life.
05

The majority of CNS medicines are classified as Schedule H / H1 prescription drugs — requiring specific labelling declarations, prescription-only supply chain documentation and storage condition compliance. 9M India's manufacturing and quality systems are fully aligned with Schedule H regulatory requirements. All CNS formulations are supported by DCGI approvals, WHO-GMP Certificate, COA, COC, stability data and product dossiers for institutional tender and export submission.

Dosage Forms

CNS formulations across dosage forms

Tablets
- Standard
- Film-coated
- Extended-release
- ODT
- Chewable
- Antidepressants
- Antiepileptics
- Antipsychotics
- Anxiolytics
- Sertraline
- Levetiracetam
- Carbamazepine
- Haloperidol
- Clonazepam
Capsules
- Hard gelatin
- Immediate-release
- SSRIs
- Antiepileptics
- Fluoxetine
- Gabapentin
- Pregabalin
Oral Liquids (Syrups, Suspensions & Solutions)
- Oral solution
- Suspension
- Syrup
- Antiepileptics
- Sedatives
- Antihistamine-CNS
- Levetiracetam solution
- Carbamazepine suspension
- Diazepam solution
- Promethazine

Why Choose Us

Why choose 9M India for CNS drug manufacturing

Antiepileptics with narrow therapeutic index. Validated to the required standard.

Levetiracetam, Carbamazepine, Phenytoin, Valproate — antiepileptics where dose accuracy is not negotiable. Every batch tested by validated HPLC assay methods with enhanced content uniformity protocols. Not claimed — documented.
Paediatric antiepileptic oral solutions. Ready for institutional supply.

Levetiracetam oral solution and Carbamazepine suspension — specifically manufactured for paediatric epilepsy patients in NHM, district hospital and international export supply programmes. Age-appropriate dosing, validated dose uniformity, child-resistant closures as standard.
Schedule H compliant from manufacturing to dispatch.

CNS medicines require Schedule H-aligned labelling, storage and documentation across the full supply chain. Our manufacturing and quality systems are fully compliant — zero documentation gaps from batch release to institutional delivery.

Our CNS / Neurology Range

Key CNS formulations manufactured at 9M India

01

Sertraline | Antidepressant | Film-coated tablet | SSRI
02

Fluoxetine | Antidepressant | Capsule | SSRI
03

Escitalopram | Antidepressant | Film-coated tablet | SSRI
04

Clonazepam | Anxiolytic / Antiepileptic | Tablet | Benzodiazepine
05

Haloperidol | Antipsychotic | Tablet | Typical antipsychotic
06

Risperidone | Antipsychotic | Film-coated tablet | Atypical antipsychotic
07

Olanzapine | Antipsychotic | Standard / ODT | Atypical antipsychotic
08

Levetiracetam | Antiepileptic | Tablet + Oral solution | 3rd gen antiepileptic
09

Carbamazepine | Antiepileptic | Tablet + Suspension | Anticonvulsant
10

Phenytoin | Antiepileptic | Tablet | Hydantoin anticonvulsant
11

Gabapentin | Antiepileptic / Neuropathic pain | Capsule | GABA analogue
12

Pregabalin | Antiepileptic / Neuropathic pain | Capsule | GABA analogue

We keep answer short

Frequently asked questions —
CNS drug manufacturing

01

Antidepressants (SSRIs), anxiolytics (benzodiazepines), antipsychotics (typical and atypical), antiepileptics (multiple generations) and sedatives — across tablets, capsules, oral solutions, suspensions and syrups.
02

Yes — Levetiracetam oral solution (100mg/mL) and Carbamazepine suspension (100mg/5mL) specifically for paediatric epilepsy. Dose uniformity validated throughout shelf life with child- resistant closures and calibrated dosing syringes.
03

Enhanced blend uniformity validation, stratified content uniformity sampling and validated HPLC assay methods are applied to all antiepileptic formulations. Batch release requires demonstration of content uniformity within tighter acceptance criteria than standard medicines.
04

Yes — antiepileptic formulations are core items in government and NHM essential medicine programmes. DCGI-approved with documentation pre-prepared for bid submission.
05

Yes — all Schedule H and H1 CNS formulations are manufactured, labelled, stored and documented in full compliance with Schedule H regulatory requirements under the Drugs and Cosmetics Act.